PATENT CLAIM ANALYSIS

Application Number: 15891492
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "012700"]

Abstract:
The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Claim (Index 37):
The modified relaxin polypeptide of  claim 1 , wherein the relaxin polypeptide comprises the relaxin A chain polypeptide of SEQ ID NO: 4 and the relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6, substituted with a non-naturally encoded amino acid at A chain residue 1;\n wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine linked to said pharmacokinetic enhancer which comprises a peptide component comprising GGGGS-Glu \u03b3  (SEQ ID NO: 139); and a half-life extending moiety comprising -C14-COOH.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 88.0
- Lexical Diversity: 1.40476
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13774349', '15386347', '15239277', '13212101', '14152302']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7556484278121212
- 35 USC 102 Novelty (BERT): 0.5735383381222323
- Combined Prediction Score: 0.7374374188431323
- Mean Citation Score: 442.75909400000006
- Max Citation Score: 465.6355
- Similarity Product: 387.0950400951803

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test